Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RUNX1
REST API REST API
Homo sapiens
RUNX1 is differentially expressed in 422 experiments: 188 organism parts: kidney, bone marrow, ... (186 more);, 322 disease states: normal, glioblastoma, ... (320 more);, 138 cell types 557 cell lines 62 compound treatments and 93 other conditions.
Synonyms AML1, AMLCR1, PEBP2A2, CBFA2
Orthologs ENSCING00000002253 (Ciona intestinalis)   RUNX1 (Danio rerio)   Runx1 (Rattus norvegicus)   RUNX1 (Bos taurus)   Q90813_CHICK (Gallus gallus)   Runx1 (Mus musculus)   RunxB (Drosophila melanogaster)   RunxA (Drosophila melanogaster)   run (Drosophila melanogaster)   lz (Drosophila melanogaster)   runx1 (Xenopus laevis)   RUNX1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, intracellular membrane-bounded organelle, transcription factor binding, hemopoiesis, ATP binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, neuron development, protein homodimerization activity, positive regulation of transcription, DNA-dependent, calcium ion binding, embryonic hemopoiesis, central nervous system development, peripheral nervous system neuron development, negative regulation of granulocyte differentiation, in utero embryonic development, definitive hemopoiesis, myeloid progenitor cell differentiation, response to retinoic acid, skeletal system development, liver development, positive regulation of granulocyte differentiation, positive regulation of angiogenesis, behavioral response to pain, myeloid cell differentiation, sequence-specific DNA binding transcription factor activity, repressing transcription factor binding
InterPro Term AML1_Runt, AML1/Runt_N, RunxI, TF_Runt-rel_RUNX
UniProt Accession A8MZI9, C9JFJ4, Q01196, C9JK12, C9JWM1, F5H139
Gene-Disease Assocation PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY, LEUKEMIA, ACUTE MYELOID; AML, RHEUMATOID ARTHRITIS; RA
Search EB-eye ENSG00000159216
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-22541, E-GEOD-1577, ... (38 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (55 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
HCC2157
2
E-MTAB-37, E-MTAB-62
551 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (70 experiments)

Factor Value U/D Experiments
epithelial cell
3
E-MEXP-2034, E-GEOD-4483, E-GEOD-10797
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
132 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (96 experiments)

Factor Value U/D Experiments
glioblastoma
1
5
E-GEOD-4290, E-MEXP-567, E-GEOD-6014, E-MTAB-37, E-GEOD-4412, ... (6 experiments)
colon carcinoma
3
E-MTAB-62, E-MTAB-57, E-MTAB-37
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
acute promyelocytic leukemia
1
3
E-MTAB-62, E-GEOD-995, E-GEOD-96, E-GEOD-1729
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MEXP-66, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-1004, E-GEOD-3307
316 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-4748, ... (38 experiments)

Factor Value U/D Experiments
none
4
10
E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-MEXP-1230, ... (14 experiments)
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
sapphyrin PCI-2050
1
E-GEOD-6400
PGE2
1
E-MEXP-1230
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
1mM GDC-0941
1
1
E-GEOD-20719
56 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
39 years
1
1
E-GEOD-4922
40
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-TABM-255, E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-1561, ... (10 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-21612, E-GEOD-20540, ... (19 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-2466, E-MEXP-2069, ... (46 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (10 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (7 experiments)

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Processing time: 0.585 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM